A Randomized Double-blind Placebo-controlled Phase I Study on the Safety, Tolerability and Pharmacokinetics/-Dynamics of Escalating Single Intravenous Doses of ADRECIZUMAB (HAM8101) in Healthy Male Subjects During Experimental Endotoxemia
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 19 Dec 2018
At a glance
- Drugs Adrecizumab (Primary)
- Indications Septic shock
- Focus Adverse reactions
- Sponsors Adrenomed
- 19 Dec 2018 According to an Adrenomed media release, results of the two phase I trials (NCT02991508 and NCT03083171) were presented by Dr. Jens Zimmermann (Chief Medical Officer of Adrenomed AG) at the 2nd scientific symposium (Endothelial Dysfunction-Adrenomedullin as a diagnostic and therapeutic target) which was hosted by Adrenomed AG.
- 01 Jun 2018 Results assessing safety, tolerability and PK/PD of Adrecizumab in two randomised studies ( NCT02991508 and NCT03083171) published in the British Journal of Clinical Pharmacology
- 25 Sep 2017 According to an Adrenomed media release, Dr Christopher Geven is lead investigator of this and other Phase I study (see profile 279742).